C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality

Summary

Previous studies have shown an association between serum C-reactive protein (CRP) and cardiovascular disease (CVD) risk. The roles of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) are less well established. The aim of the present study was to analyze the associations of CRP, IL-6 and TNFα with incident coronary heart disease (CHD) events, CVD events, and total mortality. A random population sample, including men and women aged 25–64 years was examined in Finland in 1992.The sample size was 7,927 and 6,051 (76%) participated. The cohort was followed up until the end of 2001. During the follow-up, 151 incident CHD events, 205 CVD events and 183 deaths from any cause were observed. A stratified random subsample (n=313) was used as the comparison group. After adjustment for conventional CVD risk factors, CRP showeda significant association with CHD risk in men (HR=2.39, 1.08–5.28, comparing fourth quartile to the first quartile).This association remained significant after further adjustment for TNFα. TNFα also was a significant predictor of CHD among men, but the association was nonlinear (HR=2.21, 1.18–4.14 comparing the three upper quartiles to the first quartile). Further adjustment for CRP did not change this association substantially. Both CRP and TNFα predicted also all CVD events and total mortality among men. Among women the findings were nonsignificant. In conclusion, CRP andTNFα were significant, independent predictors of CHD and CVD events and total mortality among men. These findings provide further support to the important role of inflammation in the pathogenesis of CVD.

Keywords

Cardiovascular disease - cytokines - inflammation - myocardial infarction

• References

• 1 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
• 2 Pearson TA, Mensah GA, Alexander RW. et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
• 3 Danesh J, Whincup P, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000; 321: 199-204.
• 4 Cesari M, Penninx BWJH, Newman AB. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation 2003; 108: 2317-22.
• 5 Ridker PM. High-sensitivity c-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.
• 6 Danesh J, Wheeler JG, Hirschfield GM. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
• 7 Luc G, Bard JM, Juhan-Vague I. PRIME Study Group. et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-61.
• 8 Cushman M, Arnold AM, Psaty BM. et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation 2005; 112: 25-31.
• 9 Ridker PM, Hennekens CH, Buring JE. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
• 10 Wilson PWF, Nam B-H, Pencina M. et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165: 2473-8.
• 11 Pai JK, Pischon T, Ma J. et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
• 12 Ridker PM, Rifai N, Stampfer MJ. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
• 13 Vartiainen E, Puska P, Jousilahti P. et al. Twentyyear trends in coronary risk factors in North Karelia and in other areas of Finland. Int J Epidemiol 1994; 23: 495-504.
• 14 The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988; 41: 105-14.
• 15 Salomaa V, Koukkunen H, Ketonen M. et al. for the FINAMI Study Group. A new definition for myocardial infarction: what difference does it make?. Eur Heart J 2005; 26: 1719-25.
• 16 Sivenius J, Tuomilehto J, Immonen-Räihä P. et al. FINSTROKE study. Continuous 15-year decrease in incidence and mortality of stroke in Finland: the FINSTROKE study. Stroke 2004; 35: 420-5.
• 17 Pajunen P, Koukkunen H, Ketonen M. et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132-7.
• 18 Mähönen M, Salomaa V, Torppa J. et al. The validity of the routine mortality statistics on coronary heart disease in Finland: comparison with the FINMONICA MI register data for the years 1983-1992. Finnish multinational MONItoring of trends and determinants in CArdiovascular disease. J Clin Epidemiol 1999; 52: 157-66.
• 19 Leppälä JM, Virtamo J, Heinonen OP. Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland. Eur J Epidemiol 1999; 15: 155-60.
• 20 Prentice RL. On the design of synthetic case-control studies. Biometrics 1986; 42: 301-10.
• 21 Berthier F, Lambert C, Genin C. et al. Evaluation of an automated immunoassay method for cytokine measurement using the Immulite immunoassay system. Clin Chem Lab Med 1999; 37: 593-9.
• 22 Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994; 50: 1064-72.
• 23 Barlow WE, Ichikawa L, Rosner D. et al. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-72.
• 24 SAS Institute Inc. User’s Guide, Statistics, Version 8. Cary, USA: SAS Institute, 1999; vol 1 3884.
• 25 Jousilahti P, Vartiainen E, Alho H. et al. Opposite associations of cardbohydrate-deficient transferrin and γ-glutamyltransferase with prevalent coronary heart disease. Arch Intern Med 2002; 162: 817-21.
• 26 Ruttman E, Brant LJ, Concin H. The Vorarlberg Health Monitoring and Promotion Program Study Group. et al. ?-glutamyltransferase as a risk actor for cardiovascular disease mortality. An epidemiological investigation ina cohort of 163944 Austrian adults. Circulation 2005; 112: 2130-7.
• 27 Meisinger C, Lowel H, Heier M. KORA Study Group. et al. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005; 258: 527-35.
• 28 Wannamethee SG, Shaper AG, Lennon L. et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-8.
• 29 Ridker PM, Cushman M, Stampfer MJ. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl Med 1997; 336: 973-9.
• 30 Koenig W, Sund M, Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
• 31 Lowe GD, Sweetnam PM, Yarnell JW. et al. C-reactive protein, fibrin d-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-62.
• 32 Lagrand WK, Visser CA, Hermens WT. et al. C-reactive protein asa cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999; 100: 96-102.
• 33 Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
• 34 Torzewski M, Rist C, Mortensen RF. et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-9.
• 35 Li SH, Szmitko PE, Weisel RD. et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109: 833-6.
• 36 Pradhan AD, Manson JE, Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
• 37 Hu FB, Meigs JB, Li TY. et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
• 38 Jenny NS, Tracy RP, Ogg MS. et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 2066-71.
• 39 Lowe GDO, Rumley A, McMahon AD. et al. Interleukin-6, fibrin d-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.
• 40 Pradhan AD, Manson JE, Rossouw JE. et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 2002; 288: 980-7.
• 41 Undar L, Ertugrul C, Altunbas H. et al. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 1999; 81: 571-5.
• 42 Dugue B, Leppänen E. Short-term variability in the concentration of serum interleukin-6 and its soluble receptor in subjectively healthy persons. Clin Chem Lab Med 1998; 36: 323-5.
• 43 Ridker PM, Rifai N, Pfeffer M. et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
• 44 Koukkunen H, Penttilä K, Kemppainen A. et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33: 37-47.
• 45 Vasan RS, Sullivan LM, Roubenoff R. et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-91.
• 46 Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005; 25: 151-74.